SHOULDER INNOVATIONS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SI in the last 7 days.
No SEC Form 4 filings for $SI in the last 30 days.
See all $SI insider activity →Shoulder Innovations (NYSE: SI) will release Q3 2026 financial results on November 5, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results. The company focuses on shoulder surgical care technology, offering implant systems and related technologies.
Shoulder Innovations began a limited user release of its InSet Go glenoid implant after a successful first case. The next-gen design preserves the InSet principle, streamlines surgery, and includes new IP protections. The company plans a full commercial launch in coming quarters, citing strong commercial interest.
Ball Robert Joseph (CEO & Executive Chairman) sold 10,175 shares of SHOULDER INNOVATIONS, INC. (SI) at $18.45 ($0.19M total) on 2026-09-14.
Recent SI coverage spans financial news, insider activity and earnings.
This is a scheduled earnings-release setup for SI, creating a near-term catalyst window around Nov. 5 and the subsequent market reaction.
The product launch introduces a new revenue stream and may boost the stock modestly.
Insider sale may signal lack of confidence, but size is modest.
The clearance opens a new market segment for metal‑hypersensitive patients, potentially boosting sales and market share.
The collaboration could expand SI's product portfolio and drive incremental revenue.
AlphAI scores every news story that mentions SI with an AI model for sentiment and relevance, and aggregates insider trades from SHOULDER INNOVATIONS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Shoulder Innovations (NYSE: SI) will release Q3 2026 financial results on November 5, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results. The company focuses on shoulder surgical care technology, offering implant systems and related technologies.
2 min readShoulder Innovations began a limited user release of its InSet Go glenoid implant after a successful first case. The next-gen design preserves the InSet principle, streamlines surgery, and includes new IP protections. The company plans a full commercial launch in coming quarters, citing strong commercial interest.
1 min readBall Robert Joseph (CEO & Executive Chairman) sold 10,175 shares of SHOULDER INNOVATIONS, INC. (SI) at $18.45 ($0.19M total) on 2026-09-14.
1 min readShoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant
2 min readShoulder Innovations (NYSE: SI) and ALM Ortho partnered to develop personalized shoulder implants for complex cases. SI gains exclusive U.S. rights for upper extremity applications. The deal aims to address unmet needs and drive growth, though financial terms are confidential.
1 min readShoulder Innovations (NYSE: SI) settled patent litigation with Catalyst OrthoScience. Terms are confidential. The company focuses on shoulder surgical care and aims to advance arthroplasty. CEO Rob Ball emphasized protecting intellectual property to benefit stakeholders.
1 min readGilde Healthcare Holding B.V. sold 25,097 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.61 ($22.60–$22.62, $0.57M total) across 3 trades over 2026-08-20 to 2026-08-24.
1 min readShoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.
6 min readAccording to a Form 10-K filed May 13, 2026, Gilde Healthcare and related Dutch entities hold 2,212,207 shares of Shoulder Innovations, Inc. common stock, or 10.7% based on 20,738,226 shares outstanding as of May 6, 2026. The filing also reports open-market sales in late July to early August 2026, including 99,812 shares sold Aug. 4 at a weighted average $22.77.
2 min readGilde Healthcare Holding B.V. sold 9,433 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.63 ($22.60–$22.64, $0.21M total) across 2 trades over 2026-08-05 to 2026-08-06.
2 min read
